Three phase III clinical trials (Keynote 426, Checkmate 9ER and Checkmate 214) assessing first-line treatment with immunotherapy in metastatic renal cell carcinoma (RCC) compared to sunitinib were analysed for patients who had prior nephrectomy compared to those who did not. Patients who had prior nephrectomy had a longer time before the immunotherapy stopped working and […]
The use of combination therapies for the first-line treatment of metastatic renal cell carcinoma (RCC) has increased significantly over the past 3 years. However, there are now a number of potential first-line treatments, and choosing the most suitable treatment for each individual patient can be difficult. In a presentation at the European International Kidney Cancer […]
Kidney cancers frequently have mutations in the von Hippel-Lindau (VHL) gene, resulting in high levels of a protein called hypoxia-inducible factor, or HIF-2α. This results in a number of changes in the cancer cells and their surrounding environment that favour tumour growth. The novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), blocks the action of HIF-2α. In a small […]
A study published in European Urology this month looks at the use of immunotherapy combined with a vascular endothelial growth factor (VEGF) inhibitor as second-line treatment for metastatic clear cell renal cell carcinoma (RCC). The study investigates the safety and effectiveness of a combination of atezolizumab (immunotherapy) with bevacizumab (VEGF inhibitor) in the second line after […]
Previous studies have shown that cancer patients who experience immune-related side effects (immune-related adverse events) when treated with immunotherapy may have a better response to treatment. This study looks at this effect in patients with metastatic renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (immunotherapy). In the study, 43 patients with metastatic RCC were […]
This Practice Update interview with Dr Monty Pal from City of Hope Hospital, Duarte, USA and Dr Jun Gong from Cidars-Sinai Medical Centre, Los Angeles, USA reports further follow-up data from the KEYNOTE-426 clinical trial. KEYNOTE-426 is a phase 3 trial looking at the effectiveness of a combination of axitinib and pembrolizumab compared to sunitinib […]
Results from the phase 3 CLEAR study, presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium over the weekend, showed that lenvatinib used in combination with either pembrolizumab or everolimus resulted in improved survival and tumour shrinkage compared to sunitinib when used as a first-line treatment for patients with advanced renal cell […]
A gene called MET codes for a protein called MET tyrosine protein kinase (also called hepatocyte growth factor receptor), which stimulates the growth and development of tumours. MET tyrosine protein kinase is a key driver of the growth and development of papillary renal cell carcinoma (pRCC). In this study presented at the American Society of […]
In a small phase 2 study presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), the novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), showed promising anti-cancer activity in combination with cabozantinib in patients with metastatic clear cell renal cell carcinoma (RCC) that had been previously treated. Kidney cancers develop […]
Results of a retrospective study presented during the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) looked at the effect of immune checkpoint inhibitors (immunotherapy, e.g. nivolumab, ipilimumab, pembrolizumab) on the survival of patients with metastatic non-clear cell renal cell carcinoma (RCC) compared to targeted therapy with vascular endothelial growth factor (VEGF) […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
